90 related articles for article (PubMed ID: 8822909)
1. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.
Le Beau MM; Espinosa R; Davis EM; Eisenbart JD; Larson RA; Green ED
Blood; 1996 Sep; 88(6):1930-5. PubMed ID: 8822909
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.
Jerez A; Sugimoto Y; Makishima H; Verma A; Jankowska AM; Przychodzen B; Visconte V; Tiu RV; O'Keefe CL; Mohamedali AM; Kulasekararaj AG; Pellagatti A; McGraw K; Muramatsu H; Moliterno AR; Sekeres MA; McDevitt MA; Kojima S; List A; Boultwood J; Mufti GJ; Maciejewski JP
Blood; 2012 Jun; 119(25):6109-17. PubMed ID: 22553315
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
Abbas HA; Ayoub E; Sun H; Kanagal-Shamanna R; Short NJ; Issa G; Yilmaz M; Pierce S; Rivera D; Cham B; Wing S; Li Z; Hammond D; Jabbour E; Borthakur G; Garcia-Manero G; Andreeff M; Daver N; Kadia T; Konopleva M; DiNardo C; Ravandi F
Leuk Lymphoma; 2022 Dec; 63(13):3105-3116. PubMed ID: 36089905
[TBL] [Abstract][Full Text] [Related]
4. Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.
Mori M; Kubota Y; Durmaz A; Gurnari C; Goodings C; Adema V; Ponvilawan B; Bahaj WS; Kewan T; LaFramboise T; Meggendorfer M; Haferlach C; Barnard J; Wlodarski M; Visconte V; Haferlach T; Maciejewski JP
Leukemia; 2023 Oct; 37(10):2082-2093. PubMed ID: 37634012
[TBL] [Abstract][Full Text] [Related]
5. Delineation of 2q32q35 deletion phenotypes: two apparent "proximal" and "distal" syndromes.
Mc Cormack A; Taylor J; Gregersen N; George AM; Love DR
Case Rep Genet; 2013; 2013():823451. PubMed ID: 23840981
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias.
Fischer K; Fröhling S; Scherer SW; McAllister Brown J; Scholl C; Stilgenbauer S; Tsui LC; Lichter P; Döhner H
Blood; 1997 Mar; 89(6):2036-41. PubMed ID: 9058725
[TBL] [Abstract][Full Text] [Related]
7. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Wong JC; Weinfurtner KM; Westover T; Kim J; Lebish EJ; Del Pilar Alzamora M; Huang BJ; Walsh M; Abdelhamed S; Ma J; Klco JM; Shannon K
Leukemia; 2024 May; 38(5):1182-1186. PubMed ID: 38443608
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Zavras PD; Sinanidis I; Tsakiroglou P; Karantanos T
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902450
[TBL] [Abstract][Full Text] [Related]
9. When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome.
Jain N; Gautam P; Tiwari A; Mittal A; Gupta N; Yadav ML
Int J Appl Basic Med Res; 2022; 12(4):288-290. PubMed ID: 36726663
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Clonal Hierarchy and Heterogeneity on Phenotypic Manifestations of Myelodysplastic Neoplasms.
El Hussein S; Loghavi S
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428782
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic Syndrome: Diagnosis and Screening.
Tria FP; Ang DC; Fan G
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885487
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in
Carr T; McGregor S; Dias S; Verykokakis M; Le Beau MM; Xue HH; Sigvardsson M; Bartom ET; Kee BL
Front Immunol; 2022; 13():845488. PubMed ID: 35371057
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes and overlap syndromes.
Chang YH
Blood Res; 2021 Apr; 56(S1):S51-S64. PubMed ID: 33935036
[TBL] [Abstract][Full Text] [Related]
14. Engineering of targeted megabase-scale deletions in human induced pluripotent stem cells.
Kotini AG; Papapetrou EP
Exp Hematol; 2020 Jul; 87():25-32. PubMed ID: 32544417
[TBL] [Abstract][Full Text] [Related]
15. Genetics of progression from MDS to secondary leukemia.
Menssen AJ; Walter MJ
Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
[TBL] [Abstract][Full Text] [Related]
16. The role of noncoding RNAs in epithelial cancer.
Agostini M; Ganini C; Candi E; Melino G
Cell Death Discov; 2020; 6():13. PubMed ID: 32194993
[TBL] [Abstract][Full Text] [Related]
17. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.
Crisà E; Kulasekararaj AG; Adema V; Such E; Schanz J; Haase D; Shirneshan K; Best S; Mian SA; Kizilors A; Cervera J; Lea N; Ferrero D; Germing U; Hildebrandt B; Martínez ABV; Santini V; Sanz GF; Solé F; Mufti GJ
Leukemia; 2020 Sep; 34(9):2441-2450. PubMed ID: 32066866
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.
Ruiz-Gutierrez M; Bölükbaşı ÖV; Alexe G; Kotini AG; Ballotti K; Joyce CE; Russell DW; Stegmaier K; Myers K; Novina CD; Papapetrou EP; Shimamura A
JCI Insight; 2019 Apr; 5(12):. PubMed ID: 31039138
[TBL] [Abstract][Full Text] [Related]
19. Deletions of Chromosome 7q Affect Nuclear Organization and
Federico C; Owoka T; Ragusa D; Sturiale V; Caponnetto D; Leotta CG; Bruno F; Foster HA; Rigamonti S; Giudici G; Cazzaniga G; Bridger JM; Sisu C; Saccone S; Tosi S
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31027247
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
